Alnylam Pharmaceuticals, Inc. (DUL.F)
| Previous Close | 135.45 |
| Open | 134.70 |
| Bid | 136.25 x 12100 |
| Ask | 137.65 x 11900 |
| Day's Range | 134.70 - 134.70 |
| 52 Week Range | 133.40 - 195.40 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | 17.092B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.30 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 184.16 |
Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
CAMBRIDGE, Mass., April 18, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
ZacksWhy Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
CAMBRIDGE, Mass., April 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). Zilebesiran is an investigational RNAi the
